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ABSTRACT 
 
 
Neuroprogenitor cells are an important resource because of their potential to replace 
damaged cells in the brain caused by trauma and disease.  It is of great importance to 
better understand which factors influence the differentiation and migration of these cells.  
Previously it has been reported that neuroprogenitor cells undergoing apoptotic stress 
have increased levels of Amyloid precursor protein (APP) and increased APP 
expression results in glial differentiation.  APP activity was also shown to be required for 
staurosporine induced glial differentiation of neuroprogenitor cells.  Monocyte 
chemoattractant protein-1 (MCP-1) is a chemokine that is expressed during 
inflammatory.  The binding of MCP-1 to its chemokine receptor induces expression of 
novel transcription factor MCP-1 induced protein (MCPIP).  MCPIP expression 
subsequently leads to cell death. Previous studies have shown that pro apoptotic 
factors have the ability to induce neural differentiation.  Therefore, we investigated if 
MCPIP expression leads to differentiation of NT2 neuroprogenitor cells.  Results 
showed that MCPIP expression increased glial fibrillary acid protein expression and also 
caused distinct morphological changes, both indicative of glial differentiation.  Similar 
results were observed with MCP-1 treatment.  Interestingly, APP expression decreased 
in response to MCPIP.  Instead, we found APP activity regulates expression of both 
MCP-1 and MCPIP.  Furthermore, inhibition of either p38 MAPK or JAK signaling 
pathways significantly reduced APP’s effect on MCP-1 and MCPIP.  These data 
demonstrate the role APP has in glial differentiation of NT2 cells through MCP-1/MCPIP 
signaling.  It is possible that increased APP expression after CNS injury could play a 
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role in MCP-1 production, possibly promoting astrocyte activation at injured site.  We 
next investigated the effect that MCP-1 has on NT2 cell migration. Studies have shown 
that when neuroprogenitor cells are transplanted into the brain they migrate towards 
damaged areas, suggesting that these areas express factors that recruit migrating cells.  
Generally, after neuronal injury there is a neuroinflammatory response that results in 
increased chemokine production.  We demonstrate that MCP-1 significantly induces the 
migration of NT2 neuroprogenitor cells.  Activation of intracellular cyclic adenosine 
monophosphate (cAMP) or protein kinase C with forskolin and phorbol 12-myristate 13-
acetate (PMA), respectively, was able to completely abolish the MCP-1 induced 
migration.  Contrarily, neither extracellular signal-regulated kinase or p38 mitogen 
activated protein kinase was required for NT2 cells to respond to MCP-1.  Interestingly, 
APP’s ability to activate MCP-1 expression was shown to play a role in NT2 cell 
migration.  We showed that NT2 cells expressing APP were capable of inducing 
migration of other neuroprogenitor cells.  Utilizing a MCP-1 neutralizing antibody we 
discovered that APP induced migration was not caused solely by increased MCP-1 
production.  Interestingly, APP increased expression of several C-C chemokines: MCP-
1, Regulated upon Activation, Normal T-cell Expressed, and Secreted (RANTES), and 
macrophage inflammatory protein alpha (MIP-1 alpha).  This demonstrates the unique 
role APP has in regulating chemokine production, which directly affects cell migration. 
Taken together, this study provides us with a greater understanding of the mechanisms 
involved in both glial differentiation and migration of NT2 neuroprogenitor cells. 
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PART 1.  MCP-1 INVOLVEMENT IN GLIAL DIFFERENTIATION OF NT2 
NEUROPROGENITOR CELLS THROUGH APP 
 
 
Introduction 
 
Chemokines are a family of conserved cytokines that have been shown to induce 
the migration of several leukocyte subpopulations into damaged tissues.  In the adult 
brain, microglia and astrocytes are believed to be the main source of chemokine 
production(Hayashi et al. 1995; Karpus et al. 1995; Oh et al. 1999; Coughlan et al. 
2000).  The central nervous system (CNS) has been shown to produce chemokines in 
response to several inflammatory and disease conditions, including allergic encephalitis, 
Alzheimer’s disease, multiple sclerosis, ischemia-induced neurodegeneration, and 
trauma (Glabinski and Ransohoff 1999).  Monocyte chemoattractant protein-1 (MCP-1), 
a member of the C-C chemokine family, is a potent chemotactic factor for 
monocytes(Rollins 1997).  A recent study showed that the binding of MCP-1 to its 
receptor, CCR2, induces the expression of a novel transcription factor, MCP-induced 
protein or MCPIP.  MCPIP expression up regulates several pro apoptotic genes, which 
leads to cell death(Zhou et al. 2006). Other than their neuro inflammatory properties, 
chemokine function in the CNS is still not fully understood. 
Amyloid precursor protein (APP) is a ubiquitous glycoprotein receptor that is 
involved in the pathogenesis of Alzheimer’s disease.  APP undergoes enzymatic 
processing to produce fragments with various functions(De Strooper and Annaert 2000).  
One of the fragments, beta-amyloid peptide (AB), is a main constituent of senile 
plaques(De Strooper and Annaert 2000; Golde 2003) seen in Alzheimer’s disease.  
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While the physiological function of APP is not fully understood, its structure suggests 
that APP might function as a receptor via its G0 binding domain or as a ligand via its 
soluble N-terminal domain(Yamatsuji et al. 1996).  Previously, neural stem cells 
undergoing apoptotic stress showed an increase in expression of APP and the 
surrounding cells underwent glial differentiation(Marutle et al. 2007).  APP expression is 
capable of inducing glial differentiation and that neural stem cells transplanted into APP 
transgenic mice differentiated predominantly into astrocytes (Kwak et al. 2006b).  APP 
was also shown to be required in pro apoptotic factor staurosporine induced glial 
differentiation of neuroprogenitor cells (Kwak et al. 2006a). These results demonstrate 
that increased APP signaling under apoptotic conditions causes glial differentiation.   In 
this study, we demonstrate that APP is capable of inducing expression of both MCP-1 
and MCPIP.  Increased levels of MCP-1 and MCPIP were able to activate glial 
differentiation in NT2 neuroprogenitor cells. 
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Materials and Methods 
 
Cell Culture 
The NTera-2/Clone D1 cells (NT2) were plated at a density of 5 X106 per 75cm2 in 
tissue culture treated flask (Corning).  Cell culture media was Dulbecco’s modified 
Eagle’s medium with F-12 (DMEM/F12, Invitrogen), supplemented with 10% heat 
inactivated fetal bovine serum (Atlanta Biologics). An incubation chamber was used to 
maintain a humidified atmosphere of 5% CO2 and 37oC.  NT2 cells were passed twice a 
week by 0.05% Trypsin/EDTA (Invitrogen) treatment. 
Transfection 
Transfection of plasmid DNA was performed with Lipofectamine 2000 (Invitrogen). 
Transfections were performed on subconfluent NT2 cells in 6 well plates (Corning) or 35 
mm glass bottom dishes (MatTek).  Transfection efficiency was determined by 
observation of GFP expression under fluorescence microscope or immunoblot analysis 
with GFP antibody.  AICD plasmid transfection efficiency was determined by co-
transfection with GFP plasmid.   Plasmids: pEGFP-C1 (Clonetech), pCDNA4/His-Max 
TOPO (Invitrogen), pCEP-APP-GFP, MCPIP-GFP (provided by Dr. Pappachan E. 
Kolattukudy, University of Central Florida), AICD pCDNA3 APP-C59 (provided by Dr. 
Fuyuki Kametani, Tokyo Institute of Psychiatry). 
Small interference RNA 
Small interference (siRNA) for human APP695 (Accession: A33292) was designed 
using Ambion software.  Target sequence for APP695 
(5’ATCTTTGGAACAGGAAGCAG3’).  Preparation of siRNA was done using Silencer 
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Expression (Ambion).  SiRNA cassette was then subcloned into pCDNA4/His-Max 
TOPO plasmid (Invitrogen). 
Reagents and Antibodies 
Primary Antibodies: rabbit anti-GFAP (Promega); mouse anti-APP (22C11) (Chemicon); 
mouse anti-GFP (Invitrogen); rabbit anti-Beta Actin (Cell Signaling); mouse anti-Cleaved 
PARP (Cell Signaling); mouse anti-ERK; mouse anti-ERK1/2 (pT202/pY204) (BD 
Biosciences); rabbit ant-STAT3 (BD Biosciences); rabbit anti-STAT3 (pY705) (Cell 
Signaling); mouse anti-p38 MAPK; mouse anti-p38 MAPK (pT180/pY182) (BD 
Biosciences).  Secondary antibodies:  anti-mouse IgG and anti-rabbit IgG horseradish 
peroxidase-conjugated antibodies (Amersham); TRITC conjugated antibody (Jackson 
Immuno). Reagents and Kinase Inhibitors: Secreted type Amyloid Precursor protein 
alpha S9564-25UG (Sigma).  Trypan blue (Sigma);  JAK1 inhibitor (calbiochem); p38 
MAPK inhibitor-SB203580 (Sigma); and ERK1/2 inhibitor-PD098059 (Sigma).  Cells 
were pretreated with kinase inhibitors for 45 mins prior to plasmid transfection.     
Immunoprecipitation and Immunoblot analysis 
Protein samples were collected from cells lysed by ice cold lysis buffer consisting of 1% 
NP40, 150mM NaCl, 50mM Tris, pH 8.0 and protease inhibitor cocktail (Calbiochem).  
The protein concentration was measured using Bradord reagent (BioRad).  For 
immunopreciptation experiment cell lysates were immunoprecipitated with an antibody 
against ERK, STAT3, p38 MAPK using protein G-Sepharose (Amersham Bioscience).  
Then precipitates or cell lysates were heated at 90˚C for 10 min in a sample loading 
buffer and separated on NuPAGE 4-12% Bis-Tris Gel (Invitrogen) for 60 mins at 200 V 
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and subsequently transferred to a PVDF membrane (30 V for 90 mins).  Membranes 
were incubated in blocking solution (5% milk in PBS with 0.05% Tween 20 (PBS-T) 
(Invitrogen) for 2 hours at room temperature (RT).  Membranes were probed with 
primary antibody in blocking solution overnight at 4˚C.  The membranes were washed 
three times for 5 mins with PBS-T and then incubated with horseradish peroxidase 
conjugated secondary antibodies in blocking solution for 2 hours at RT. After three 
washes with PBS-T protein bands were visualized with ECL plus chemilluminescence 
reagent (Amersham Bioscience).  Immunoblot images were captured by KODAK Image 
Station 2000MM.  Protein values were normalized to Beta Actin expression.  Image 
analysis and data normalization was done using ImageJ 4.10 software (NIH). 
Immunocyotohemistry 
Cells were fixed in 4% paraformaldehyde 30 mins at RT, washed three times for 5 mins 
in PBS, then incubated in PBS-T for 1 hour at RT.  Cells were then blocked with 3% 
Normal Donkey Serum in PBS-T (blocking solution). Next, samples were incubated with 
primary antibody diluted in blocking solution for 2 hours at RT.  Cells were washed three 
times for 5 mins in PBS prior to adding secondary antibody, diluted in blocking solution.  
Secondary antibody incubation was done overnight at 4˚C.  Cells were then washed 
thoroughly and air-dried prior to adding Vectashield mounting media with DAPI (Vector). 
Microscopy 
Imaging was done using an inverted fluorescent microscope (Leica DMI 6000B) with 
differential interphase contrast (DIC).  DAPI/Rhodamine/FITC filter cube (Chroma) was 
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utilized for fluorescent microscopy.  Image analysis was done using Openlab Software 
4.0.1 (Improvision) 
Quantitative RT-PCR 
Total RNA was extracted from the cells with Trizol reagent (Invitrogen).  cDNA synthesis 
and RT-PCR reactions were performed using iQ SYBER Green Supermix (Biorad). RT-
PCR conditions were pre denaturation for 2 mins at 94˚C; 35 cycles of 94˚C for 15 s: 
55-60˚C for 30 s; and 72˚C for 30 s; and a post extension at 72˚C for 2 mins.  RT-PCR 
reaction was performed using iCycler (Biorad).  Fold change was determined using the 
pfaffl method (Pfaffl 2001).   
RT-PCR Primers 
GFAP (+) 5-AAGCAGTCTACCCACCTCAG-3,  
(-)5-ATCCCTCCCAGCACCTCATC-3;  
APP (+) 5-CTTGAGTAAACTTTGGGACATGGCGCTGC-3,                 
(-)5-GAACCCTACGAAGAAGCC-3;   
Beta Actin (+) 5-GACAGGATGCAGAAGGAGAT-3,  
(-) 5-TTGCTGATCCACATCTGCTG-3; 
MCP-1 (+) 5-GCGAGCTATAGAAGAATCACC-3,  
(-) 5-ATAAAACAGGGTGTCTGGGG-3; 
MCPIP (+) 5-AACTGGAGAAGAAGAAGATCCTGG-3,  
(-) 5-ATTGACGAAGGAGTACATGAGCAG-3 
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Statistical analysis 
 
Experiments were done in triplicate and standard deviation was determined.  A T-test 
analysis was performed to determine statistical significance of experimental group 
compared to control group. 
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Results 
 
Cell death caused MCPIP expression 
The transcription factor MCPIP has previously been shown to induce apoptosis in 
various cell lines(Hausmann et al. 1998; Zhou et al. 2006). To determine the effect 
MCPIP has on NT2 cells, we performed a cell death dye exclusion assay utilizing trypan 
blue.  NT2 cells were transfected with either GFP (control) or MCPIP-GFP and analyzed 
1, 3, and 5 days post transfection.  Results showed that MCPIP expression caused a 
significant increase in cell death compared to control at all indicated time points (Figure 
1).  Day 5 showed the most significant increase in cell death, with MCPIP at 53.65% 
compared to 26.7% for GFP.  As expected, plasmid transfection caused low levels of 
cell death as seen in GFP transfected cells.  We also showed that MCPIP induced 
apoptosis in NT2 cell by immunoblot analysis with anti cleaved PARP antibody.  These 
results demonstrate that MCPIP expression in NT2 neuroprogenitor cells induces 
apoptosis, as previously seen in other cell lines. 
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Figure 1  MCPIP increases cell death in NT2 cells 
(A) Percent cell death after MCPIP-GFP or GFP (Control) transfection.  Cells were 
harvested at 1, 3, 5 days post transfection.  Cell death was detected by trypan blue.  (B) 
Immunoblot analysis of GFP expression and PARP cleavage in NT2 cells transfected 
with MCPIP-GFP or GFP.  Analyzed 5 days post transfection. Protein values were 
normalized to Beta Actin expression.  GFP expression demonstrates equal transfection 
efficiency.  Note: MCPIP-GFP was approximately 90kDa compared to GFP alone (27 
kDa).  * Indicates statistical significance (**P<0.01, ***P<0.001). 
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Induction of glial differentiation by MCPIP expression in NT2 cells 
Previously, pro apoptotic factors have been shown to be involved neural 
differentiation (Kwak et al. 2006a).  Therefore, we investigated if the pro apoptotic 
nature of MCPIP could induce differentiation in NT2 neuroprogenitor cells.  The results 
showed that MCPIP caused a significant increase in GFAP mRNA, indicative of glial 
differentiation (Figure 2A).  Immunoblot analysis with GFAP specific antibody confirmed 
these results (Figure 2B).  Immunocytochemistry showed increased levels of GFAP 
expression, as well as distinct astrocyte morphology for MCPIP transfected cells (Figure 
2C and 2D).  Taken together, these results demonstrate that MCPIP expression is 
capable of inducing glial differentiation in NT2 cells. 
 
 10
 
Figure 2  Increased glial fibrillary acidic protein expression and morphological 
changes caused by MCPIP expression 
(A) RT-PCR analysis of GFAP in NT2 cells transfected with MCPIP-GFP or GFP 
(control) 24 hours post transfection.  Figure represents fold change vs. control.  (B) 
Immunoblot analysis of GFAP in cells transfected with MCPIP-GFP or GFP, analyzed 
24 hours post transfection.  Protein values were normalized to Beta Actin expression.  * 
Indicates statistical significance (*P<0.05, ***P<0.001).  Immunocytochemistry showing 
GFAP expression in NT2 cells transfected with GFP (C) or MCPIP-GFP (D).  Analyzed 
24 hours post transfection.  Scale bar in panel represents 15 µm. 
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Induction of glial differentiation by MCP-1 treatment in NT2 cells  
It is already shown that MCP-1 is responsible for activation of transcription factor 
MCPIP.  Therefore, we tested MCP-1 for its ability to induce glial differentiation.  The 
RT-PCR results showed that MCP-1 caused a significant increase in GFAP expression 
at 24 hours, especially for 100ng/ml and 300ng/ml concentrations (Figure 3A).  
Immunoblot analysis with anti GFAP antibody confirmed these results (Figure 3B).  
Increased GFAP expression and morphological changes indicative of astrocytic 
differentiation were also observed for MCP-1 treated cells (Figure 3C and 3D).  These 
results demonstrate that MCP-1 activates glial differentiation in a similar manner as 
MCPIP.  
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Figure 3  Increased glial fibrillary acidic protein expression and morphological 
changes caused by MCP-1 
(A) RT-PCR analysis of GFAP in NT2 cells treated with MCP-1 at indicated 
concentrations.  Analyzed 24 hours post treatment.  Figure represents fold change vs. 
control (untreated).  (B) Immunoblot analysis of GFAP in cells treated with MCP-1 or 
untreated after 24 hours.  Protein values were normalized to Beta Actin expression.  * 
Indicates statistical significance (*P<0.05, **P<0.01). Immunocytochemistry showing 
GFAP expression in NT2 cells untreated (C) or treated with MCP-1 (100ng/ml) (D).  
Analyzed 24 hours after treatment.  Scale bar in panel represents 15 µm. 
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MCPIP expression decreases amyloid precursor protein levels 
Previously, staurosporine induced glial differentiation of NT2 cells was shown to 
require APP expression(Kwak et al. 2006a).  Therefore, we expected that MCPIP 
expression might increase APP levels, and that APP activity could play a significant part 
in the differentiation process.  Interestingly, results showed that MCPIP expression 
significantly decreased APP mRNA and protein levels in NT2 cells (Figure 4A and B).  
This data suggests that MCPIP induced glial differentiation does not require increased 
APP expression, as previously seen with staurosporine. 
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 Figure 4  MCPIP decreases APP mRNA and protein levels 
(A) RT-PCR analysis of APP expression in cells transfected with MCPIP-GFP or GFP 
(control).  Analyzed 24 hours post transfection.  (B) Immunoblot analysis of APP 
expression in NT2 cells transfected with MCPIP-GFP or GFP control.  Analyzed 24 
hours post transfection.  Protein values were normalized to Beta Actin expression.  
Figure represents fold change vs. control. * Indicates statistical significance (*P<0.05). 
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Amyloid precursor protein induces expression of MCP-1 and MCPIP. 
Contrary to our initial hypothesis, MCPIP expression decreased APP activity.  It 
is possible that APP may act upstream of MCPIP and APP might be able to regulate 
MCPIP activity.  Therefore, we investigated if APP expression is capable of increasing 
MCPIP and MCP-1.  The results showed that 24 hours post APP transfection both 
MCP-1 and MCPIP expression significantly increased (Figure 5).  Gene silencing of 
APP by siRNA significantly suppressed normal levels of both MCP-1 and MCPIP mRNA 
expression in NT2 cells (Figure 5).  These results suggest that MCP-1 and MCPIP 
expression is effectively regulated by APP signaling.  
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Figure 5  APP expression regulates MCP-1 and MCPIP mRNA 
RT-PCR analysis of APP, MCP-1, and MCPIP in NT2 cells transfected with APP-GFP, 
siAPP, or GFP (control).  Analyzed 24 hours post transfection.   Figure represents fold 
change vs. control.  * Indicates statistical significance (*P<0.05, **P<0.01, ***P<0.001). 
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Secreted type APP alpha and APP intracellular domain effect on MCP-1 and MCPIP 
We next tested whether the processed forms of APP, secreted type APP alpha 
(sAPPα) and APP intracellular domain (AICD), have an effect on MCP-1 and MCPIP 
expression.  We treated NT2 cells with sAPPα at 25, 50, and 100nM concentrations and 
measured MCP-1 and MCPIP expression by RT-PCR.  Results showed that sAPPα 
significantly increased MCP-1, but not to the same extent as transfected full length APP 
(Figure 6A).  Interestingly, MCPIP expression did not increase in response to either 
sAPPα or AICD.  Increasing the concentration of sAPPα did not elevate MCP-1 levels 
any further, demonstrating its effect was not dose dependent (Figure 6A).  Similar 
results were observed after NT2 cells were transfected with AICD plasmid (Figure 6B).  
In conclusion, these results show that both processed forms of APP, sAPPα and AICD, 
are capable of increasing expression of MCP-1, but not MCPIP. 
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Figure 6  Secreted APP alpha and APP intracellular domain (AICD) effect on MCP-
1 and MCPIP 
(A) RT-PCR analysis of MCP-1 and MCPIP in NT2 cells treated with secreted type APP 
alpha (25, 50, 100nM) or transfected with AICD (B).  RT-PCR analysis of MCP-1 and 
MCPIP in NT2 cells transfected with AICD or GFP (control).Figure represents fold 
change vs. control (GFP).  Analyzed 24 hours post treatment/transfection. Indicates 
statistical significance (*P<0.05, **P<0.01) 
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Amyloid precursor protein’s effect on MCP-1 and MCPIP expression relies on p38 
MAPK and JAK/STAT signaling 
 
We have shown that APP can increase MCP-1 and MCPIP expression.  Next, we 
examined which signal transduction pathways are involved in this process.  In order to 
determine what mechanism APP uses in its induction of MCP-1 and MCPIP we 
investigated the p38 mitogen-activated protein kinase (MAPK), extracellular signal-
related protein kinase (ERK1/2), and Janus activated kinase (JAK) signal transduction 
pathways.  NT2 cells were pretreated with p38 (SB203580), ERK1/2 (PD098059), and 
JAK1 inhibitors for 45 minutes at 25uM, 50uM, and 250nM, respectfully.  Samples were 
then transfected with APP-GFP or GFP and analyzed 24 hours post transfection.  
Results showed that the p38 MAPK and JAK specific inhibitors caused a significant 
decrease in both MCP-1 and MCPIP (Figure 7A).  The ERK1/2 inhibitor, PD098059, 
had no effect on either MCP-1 or MCPIP activity.  Similar results were observed using 
increased concentrations of ERK1/2 inhibitor (data not shown).  In addition, we also 
investigated the phosphorylated state of the specific proteins involved in these 
pathways.  Results showed that APP expression increased phosphorylation of both p38 
and STAT3 (Figure 7B).  There was no increase in phosphorylation of ERK1/2 proteins, 
confirming the results obtained using PD098059.  These results indicate that APP relies 
on activation of both p38 MAPK and JAK/STAT3 signaling pathways to induce MCP-1 
and MCPIP expression.  
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Figure 7  APP’s effect on MCP-1 and MCPIP expression relies on p38 MAPK and 
JAK/STAT signaling 
(A) RT-PCR analysis of MCP-1 and MCPIP in NT2 cells transfected with APP.  NT2 
cells were pretreated for 45 mins with 50uM of ERK1/2 inhibitor (PD098059), 25uM of 
p38 MAPK inhibitor (SB203580), 250nM of JAK1 inhibitor, or untreated.  NT2 cells were 
then transfected with APP-GFP or GFP (control).  Figure represents fold change over 
control (GFP). Analyzed 24 hours post transfection.  (B) Immunoblot analysis of 
Phosphorylated ERK (pT202/pY204), p38 MAPK (pT180/pY182), and STAT3 (pY705).  
Prior to immunoblot analysis cell lysates were immunoprecipitated with anti ERK1/2, 
p38 MAPK or anti STAT3, respectively.  Basal levels of phosphorylation was observed 
for controls, as expected.  * Indicates statistical significance (*P<0.05, **P<0.01, 
***P<0.001). 
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Discussion 
 
Our study characterizes the involvement APP and chemokine MCP-1 have in 
glial differentiation of NT2 neuroprogenitor cells.  NT2 cells have the ability to develop 
into both mature neurons and astrocytes, making them an attractive in vitro model 
system for analyzing neural differentiation(Bani-Yaghoub et al. 1999; Kwak et al. 
2006a).  It has been reported that apoptosis was closely associated with neural 
differentiation(Oppenheim 1991) and that pro apoptotic factors could induce glial 
differentiation in NT2 cells(Kwak et al. 2006a).  Therefore, we investigated the effect 
transcription factor MCPIP has on cell death and differentiation in NT2 cells.  Results 
showed that MCPIP expression not only induced cell death, but also promoted 
increased expression of GFAP and astrocyte cell morphology, indicative of glial 
differentiation.  Similar results were seen with MCP-1 treatment, particularly at higher 
concentrations.  Lower concentrations of MCP-1 were unable to induce expression of 
GFAP or cause any morphological changes.  This suggests that low concentrations of 
MCP-1 may not be sufficient enough to activate MCPIP to the level needed to induce 
glial differentiation.   
We have previously demonstrated APP’s involvement in glial differentiation of 
neural stem cells and that APP expression was required in staurosporine induced 
astrocytic differentiation in NT2 cells.  Staurosporine treated cells underwent apoptosis, 
resulting in increased expression of APP.  This increase in APP was responsible for 
induction of glial differentiation (Kwak et al. 2006a).  Therefore, we investigated if APP 
has a similar role in MCPIP induced cell death and glial differentiation.  Unexpectedly, 
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we found that MCPIP expression significantly reduced APP levels.  This suggests that 
increased APP expression is not responsible for inducing glial differentiation, as 
previously seen with staurosporine treatment.  Instead, we found that APP activity could 
directly regulate expression of both MCP-1 and MCPIP.  Secreted type APPα or AICD 
were also able to significantly increase MCP-1 expression, but not to the extent that 
transfected APP obtained.  Interestingly, both processed forms of APP had no effect on 
MCPIP activity.  Given that MCP-1 is required to induce MCPIP activity, the increase 
resulting from sAPPα and AICD might not be sufficient to reach the threshold needed to 
induce MCPIP.  This suggests that sAPPα and AICD are not solely responsible for 
MCP-1 and MCPIP activation.  It is possible that their combined effect is needed or 
amyloid beta (Aβ), the other processed form of APP, is required to fully activate MCPIP 
activity.  Further investigation is necessary to better understand the effect APP 
processing has on MCP-1/MCPIP expression.  Previously, APP expression has been 
shown to increase in response to cell death (Lesort et al. 1997; Kinoshita et al. 2002; 
Nishimura et al. 2003).  The increased APP expression has been attributed to its anti-
apoptotic abilities, where it functioned as a neuroprotective factor(Lesort et al. 1997; 
Kinoshita et al. 2002).  Activation of chemokine MCP-1 can be part of APP’s 
neuroprotective function, where it helps facilitate neuroinflammation and astrocyte 
activation at site of injury.  
Through use of signaling pathway inhibitors, we investigated the mechanism by 
which APP regulated MCP-1 and MCPIP expression.  Results showed that ERK1/2 
activity, previously shown to be required for APP expression, was not required for APP’s 
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activation of MCP-1 and MCPIP (Liu et al. 2003; Kwak et al. 2006a).  Interestingly, both 
JAK and p38 MAPK inhibitors were able to suppress APP function.  Increased 
phosphorylation of both p38 MAPK and STAT3 was also observed, further confirming 
the results.  It has been reported that JAK/STAT signaling was involved in regulating 
differentiation of cerebral cortical precursor cells (Bonni et al. 1997; Rajan and McKay 
1998).  STAT3 was shown to mediate astrocyte differentiation in the developing fetal 
mouse brain(Yanagisawa et al. 1999).  In addition, the p38 MAPK pathway was shown 
to be required for MCP-1 production (Wong et al. 2005) and APP mediated anti-
apoptotic signaling (Burton et al. 2002).  Overall, both signaling pathways appear to play 
a specialized role in this APP/MCP-1 induced glial differentiation of NT2 
neuroprogenitor cells. 
Astrocytes have been identified as the primary source of MCP-1 in the brain in 
response to multiple sclerosis, ischemic brain injury, and brain trauma (Glabinski and 
Ransohoff 1999).  Increased expression of MCP-1 is present in senile plaques, 
microglia, and microvessels in Alzheimer’s disease(Ishizuka et al. 1997; Grammas and 
Ovase 2001).  It was shown that mice over expressing both APP and MCP-1 had 
microglia accumulation in the brain (Sadowski et al. 2004). It is possible that MCP-1 is 
involved in the pathogenesis of several neuropathies by the recruitment of activated 
monocytes and/or microglia into the CNS, where they produced neurotoxic and 
inflammatory molecules.  Although it has been shown that MCP-1 mediates 
inflammation in the CNS, it is still unknown if MCP-1 has alternative cellular functions in 
the brain(Ransohoff and Tani 1998; Cardona et al. 2003).  Activation of glial 
 24
differentiation could be another function of MCP-1 during neuroinflammation.  It is 
already established that astrocytes play an important role in injury repair and are the 
main source of MCP-1 production(Glabinski and Ransohoff 1999; Sofroniew 2005).  
Therefore, it is possible that MCP-1 induced glial differentiation is a repair mechanism 
that increases production of astrocytes, facilitating rapid recovery.  Unfortunately, 
astrocyte activation after injury can also have negative effects.  Increased astrocyte 
production can result in excess inflammation, toxic edema, cytotoxin production, and 
formation of glial scar, preventing effective repair(Glabinski and Ransohoff 1999; 
Sofroniew 2005).  It is essential to examine the connection between neuroinflammation 
and astrocyte activation and the role they might have in neuronal repair and protection. 
In conclusion, we propose that elevated APP levels after CNS injury can result in 
increased MCP-1 production.  This increase in MCP-1 can lead to astrocytic activation, 
eventually resulting in gliosis, causing excess damage. Further investigation is 
necessary to determine if this mechanism is responsible for the excess gliosis present 
in several neurodegenerative disorders.  This information can help provide insight on 
the factors that regulate neural differentiation in the adult brain, particularly for use in 
stem cell therapy. 
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PART 2.  APP INDUCED MIGRATION OF NT2 NEUROPROGENITOR CELLS 
INVOLVING MCP-1 
 
 
Introduction 
 
The use of neural stem cells (NSCs) to help repair damaged areas in the brain 
has been a subject of great interest.  These cells have the ability to differentiate and 
replace damaged tissue in the central nervous system (CNS) and are an attractive 
candidate for therapy of neurodegenerative diseases (Gage 2000, 2002).  The two main 
sources of these stem cells are the subventricular zone around the lateral ventricles and 
the subgranular zone of the dentate gyrus(Gage 2000; Parati et al. 2004).  
Unfortunately, clinical use of these stem cells is limited due to ethical concerns and 
technical difficulties in collecting sufficient amounts of these cells.  Instead, alternative 
sources of human neurons are being investigated.  NT2 neuroprogenitor cells, which 
are derived from a human teratocarcinoma, are an attractive alternative.  NT2 
neuroprogenitor cells are a transfectable cell line, which has the ability to proliferate in 
culture and differentiate into pure neurons(Andrews et al. 1984; Pleasure and Lee 
1993).  Once transplanted, these cells were able to survive, extend processes, and form 
functional synapses allowing them to fully integrate within the host(Kleppner et al. 1995; 
Trojanowski et al. 1997; Ferrari et al. 2000).  A better understanding of how these cells 
migrate and eventually incorporate into the CNS is of much importance.   
Research shows that when neuroprogenitors are transplanted into the brain, they 
migrate towards areas of brain damage (Fricker et al. 1999; Arvidsson et al. 2002; Iwai 
et al. 2003; Glass et al. 2005).  This suggests there are certain factors associated with 
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damaged areas in the brain and these factors recruit migrating cells.  Brain damage, 
including trauma, infection, ischemia, and neurodegeneration, generally results in a 
neuroinflammatory response, leading to activation of astrocytes and microglia.  This 
neuroinflammatory response leads to the upregulation of cytokines and chemokines 
(Huang et al. 2000).   
Chemokines are a family of conserved cytokines that have been shown to induce 
the migration of several leukocyte subpopulations into damaged tissues. Microglia and 
astroctyes are believed to be the main sources of chemokine production in the adult 
brain(Glabinski and Ransohoff 1999; Oh et al. 1999; Coughlan et al. 2000).   The CNS 
has been shown to produce chemokines in response to several inflammatory and 
disease conditions, including allergic encephalitis, Alzheimer’s disease, multiple 
sclerosis, ischemia-induced neurodegeneration, and trauma(Glabinski and Ransohoff 
1999).   
Monocyte chemoattractant protein-1 (MCP-1), a member of the C-C chemokine family, 
is a potent chemotactic factor for monocytes (Rollins 1997). MCP-1 has also been 
shown to be an effective chemoattractant to a variety of other cells types (Marra et al. 
1999; Cambien et al. 2001a; Widera et al. 2004; Yan et al. 2007).  It is proposed that 
MCP-1 is involved in the pathogenesis of several neuropathies by recruitment of 
activated monocytes and/or microglia, where they produce neurotoxic and inflammatory 
molecules.   
Previously, MCP-1’s effect on NT2 neuroprogenitor cell migration has not been 
investigated.  In this study we report MCP-1’s ability to induce migration of NT2 
 27
neuroprogenitor cells, as well as the intracellular signaling involved in the process.  We 
also discover the novel role Amyloid precursor protein has in chemokine production and 
cell migration. 
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Materials and Methods 
 
Cell Culture   
The NTera-2/Clone D1 cells, NT2 (ATCC) were plated at a density of 5 X106 per 75cm2 
in tissue culture treated flask (Corning).  Cell culture media was Dulbecco’s modified 
Eagle’s medium with F-12 (DMEM/F12, Invitrogen), supplemented with 10% heat 
inactivated fetal bovine serum (Atlanta Biologics). An incubation chamber was used to 
maintain a humidified atmosphere of 5% CO2 and 37oC.  NT2 cells were passed twice a 
week by 0.05% Trypsin/EDTA (Invitrogen) treatment.  In order to avoid any 
inconsistencies in cellular behavior, all NT2 cells used in these experiments were at 
passage number 5.
Transfection 
Transient transfection of plasmid DNA was performed with Lipofectamine 2000 
(Invitrogen) according to manufacturer’s protocol on subconfluent NT2 cells in 24 well 
plates (Falcon) or 6 well plates (Corning).  Plasmids: pCEP-APP-GFP (kindly provided 
by Dr. Beth Ostaszewski, Harvard Medical School), pEGFP-C1 (Clonetech).  
Migration Assay 
NT2 cell migration was analyzed using FluoroBlok migration insert system with 8 
micrometer pores (BD Biosciences).  Cells were pretreated with 10uM Cell tracker dye 
(Molecular probes) for 15 min prior to migration assay.  Cells were washed with 
phosphate buffered saline (PBS), trypsinized and plated in migration inserts at a density 
of 150,000 cells/cm2.  Migration inserts were then placed in a 24 well plate (Falcon) with 
specific chemoattractant in media or media alone (control).  Cells were incubated with 
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chemoattractant for up to 5 hours.  Measurement of fluorescent intensity, which 
correlates to cell migration, was carried out using a Bio-Tek microplate reader 
(excitation 480nm and emission 528nm). 
APP Induced Migration Assay  
NT2 cells were plated in a 24 well plate (Falcon) at a density of 150,000 cells/cm2 and 
transfected with GFP or APP-GFP, treated with secreted APP alpha (150nM), or left 
untreated (control).  24 hours later, migration inserts containing NT2 cells (pre treated 
with Cell tracker dye, 10uM) at a density of 150,000 cells/cm2 were placed in wells 
containing transfected/treated NT2 cells (chemoattractant).  Migration inserts were 
incubated with transfected/treated or control cells for 3 hours.  After incubation migration 
inserts were removed and placed in new well containing media only.  Measurement of 
fluorescent intensity was carried out using microplate reader (Bio-Tek). 
Quantitative RT PCR 
Total RNA was extracted from the cells in 6 well plate with Trizol reagent (Invitrogen).  
cDNA synthesis and RT-PCR reactions were performed using iQ SYBER Green 
Supermix (Biorad). RT-PCR conditions were pre denaturation for 2 mins at 94˚C; 35 
cycles of 94˚C for 15 s: 55-60˚C for 30 s; and 72˚C for 30 s; and a post extension at 
72˚C for 2 mins.  RT-PCR reaction was performed using iCycler (Biorad).  Fold change 
was determined using the pfaffl method (Pfaffl 2001). 
RT-PCR Primer Sequences: 
MCP-1 (+)5-GCGAGCTATAGAAGAATCACC-3,  
(-)5-ATAAAACAGGGTGTCTGGGG-3;  
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MCPIP (+) 5-AACTGGAGAAGAAGAAGATCCTGG-3,  
(-)5-ATTGACGAAGGAGTACATGAGCAG-3; 
MIP-1 Alpha (+) 5-TGCATCACTTGCTGCTGACACG-3 
(-) 5-CAACCAGTCCATAGAAGAGG-3 
MIP-1 Beta (+) 5-CCAAACCAAAAGAAGCAAGC-3 
(-) 5-AGAAACAGTGACAGTGGACC-3 
RANTES (+) 5-CTTTGTCACCCGAAAGAACC-3 
(-) 5-GTTTCATCATGTTGGCCAGG-3 
Beta Actin (+) 5-GACAGGATGCAGAAGGAGAT-3,  
(-) 5-TTGCTGATCCACATCTGCTG-3; 
Reagents and Antibodies  
Recombinant human monocyte chemotactic protein-1 (ABR).  Phorbol 12-Myristate 13-
acetate (PMA), 250nM (Sigma).  Forskolin, 75uM (Calbiochem).  SB203580, 25uM 
(Sigma).  PD098059, 50uM (Sigma).  Secreted amyloid precursor protein alpha 
(sAPPalpha), 150nM (Sigma). Rabbit polyclonal anti-MCP-1 (Abcam) was used to 
neutralize MCP-1 at a concentration of 10ug/ml. Anti Rabbit IgG antibody (Amersham).   
Statistical analysis 
Experiments were done in triplicate and standard deviation was determined.  A T-test 
analysis was performed to determine statistical significance (P < 0.05) of experimental 
group compared to control group. 
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Results 
Effect of MCP-1 on NT2 cell migration 
Several studies have shown MCP-1’s ability to act as a potent chemoattractant to 
various types of cells(Rollins 1997; Cambien et al. 2001b; Widera et al. 2004; Yan et al. 
2007).  We investigated the effect MCP-1 has as a chemoattractant towards NT2 
neuroprogenitor cells.  Cells were exposed to increasing concentrations of MCP-1 (10, 
20, 50, 100, 200 ng/ml) or plain media (control) for 2 to 5 hours.  Results show that 
MCP-1 acts as a strong chemoattractant in a dose and time dependent manner, with 
200ng/ml of MCP-1 for 5 hours causing the most significant effect (Figure 8).  Lower 
concentrations of MCP-1 (10ng/ml) were still sufficient to induce migration.  These 
results demonstrate that MCP-1 can induce migration of NT2 cells and confirms 
previous studies claiming MCP-1’s chemotactic ability influences many cell types. 
 
 
 
 
 
 
 32
 Figure 8  MCP-1 increases NT2 cell migration in a dose dependent manner. 
NT2 cell migration was induced with increasing concentrations of MCP-1 and compared 
to untreated controls from 2 - 5 hours.  Prior to migration assay NT2 cells were treated 
with cell tracker dye (10uM).  Cell migration was measured using fluorescent plate 
reader.  Results are shown as relative fluorescent units (RFU).  All experiments were 
done in triplicate.  Error bars represent standard deviation.  *Indicates statistical 
significance compared to control (*P<0.05). 
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Effect of pharmacologic inhibitors on NT2 cell migration towards MCP-1. 
To investigate the role of various signaling pathways on MCP-1 induced NT2 cell 
migration, we studied the effect of several pharmacologic inhibitors on MCP-1’s 
chemotactic activity.  NT2 cells were pretreated with inhibitors for 30 mins at the 
indicated concentrations prior to exposure to MCP-1.  Our results showed that 
Forskolin, which is an activator of intracellular cAMP, significantly inhibited MCP-1 
induced migration (Figure 9).  Similarly, PMA, which is a protein kinase C (PKC) 
activator, also significantly inhibited migration towards MCP-1.  In contrast, inhibition 
with PD098059 and SB203580 did not affect migration, indicating activation of 
ERK/MAPK (mitogen-activated protein kinase) and p38 MAPK do not appear to be 
required for effective response MCP-1.  Pretreatment with PD098059 and SB203580 for 
longer periods of time or higher concentrations did not have an effect (data not shown).  
This suggests that activation of ERK/MAPK and p38 MAPK are not required for 
chemotactic response to MCP-1.  Interestingly, PKC and cAMP activation are both able 
to significantly attenuate the chemotactic response to MCP-1. 
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Figure 9  Effect of pharmacologic agents on MCP-1 induced NT2 cell migration  
NT2 cells were pretreated 30 mins with following agents: PD09059 (50uM), SB203580 
(25uM), Forskolin (75uM), PMA (250nM), or left untreated (MCP-1 alone).  Cells were 
then tested for their ability to respond to MCP-1 (100ng/ml) after 3 hours of incubation. 
Cell migration was measured using fluorescent plate reader.  Results are shown as 
relative fluorescent units (RFU). All experiments were done in triplicate.  Error bars 
represent standard deviation.   *Indicates statistical significance compared to control 
(*P<0.05). 
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Chemotactic activity of APP transfected NT2 cells. 
Previously, we have shown that NT2 cells transfected with Amyloid precursor 
protein (APP) showed an increase in MCP-1 expression(Vrotsos 2007).  Therefore, we 
predict that APP transfected NT2 cells, which express MCP-1, could potentially act as a 
chemoattractant to other NT2 cells.  To test this hypothesis we transfected NT2 cells 
with APP and 24 hours later measured their ability to act as a chemoattractant for 
untreated NT2 cells.  Figure 10 shows that APP transfected cells are capable of 
inducing migration compared to control (GFP transfected).  Similarly, secreted type APP 
alpha (sAPPα) treated cells were also shown to induce NT2 cell migration.  Taken 
together, these data suggest that cells expressing increased levels of APP could act as 
a chemoattractant to migrating cells. 
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 Figure 10  Amyloid precursor protein induces NT2 cell migration. 
NT2 cells were transfected with full length APP or treated with secreted APP alpha 
(150nM) and tested for their ability to induce NT2 cell migration.  NT2 cells were 
incubated for 3 hours in the presence of transfected APP, transfected GFP, secreted 
APP alpha, MCP-1 (100ng/ml), or untreated (Control) NT2 cells, as described in 
Materials and Methods.  Cell migration was measured using fluorescent plate reader.  
Results are shown as relative fluorescent units (RFU).  All experiments were done in 
triplicate.  Error bars represent standard deviation.   *Indicates statistical significance 
compared to control (*P<0.05). 
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Effect of MCP-1 neutralization on APP induced migration. 
We have shown that NT2 cells expressing APP are capable of acting as an 
effective chemoattractant.  We next tested if increased MCP-1 production is solely 
responsible for this chemotactic response or if another factor is involved.  To investigate 
this, we utilized a MCP-1 neutralizing antibody and tested if it is capable of reducing cell 
migration.  Results showed that MCP-1 neutralizing antibody significantly reduced APP 
induced NT2 cell migration (Figure 11).  However, migration was only reduced 56% 
compared to control (IgG antibody), and was not completely abolished.  Increased 
concentrations of MCP-1 neutralizing antibody were used but did not reduce migration 
any further.  These data suggest that APP induced migration is not only caused solely 
by MCP-1, but relies on other chemotactic factors. 
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 Figure 11  MCP-1 neutralizing antibody reduces APP induced migration 
 MCP-1 antibody (10ug/ml) was used to neutralize MCP-1 protein produced by APP 
transfected NT2 cells.  Anti Rabbit IgG antibody (10ug/ml) was used as a control.  
Migration was measured in the absence or presence of neutralizing MCP-1 antibody.  
Cell migration was measured using fluorescent plate reader.  Results are shown as 
relative fluorescent units (RFU).  All experiments were done in triplicate.  Error bars 
represent standard deviation.  *Indicates statistical significance compared to control 
(IgG) (*P<0.05). 
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Amyloid precursor protein effect on chemokine expression  
We next wanted to examine if APP is capable of activating other C-C chemokines 
besides MCP-1.  Quantitative RT-PCR was done to measure any changes in the gene 
expression of MCP-1, MIP-1 alpha, MIP-1 beta, and RANTES after APP transfection.  
Results showed that NT2 cells transfected with APP caused a significant increase in 
MCP-1, MIP-1 alpha, and RANTES (Figure 12).  Interestingly, MIP-1 Beta had no 
change in gene expression in response to APP activity.  This demonstrates that APP 
activity induces expression of several chemokines. 
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Figure 12  Amyloid precursor protein effect on CC chemokine mRNA activity 
RT-PCR analysis of MCP-1, MIP-1 Alpha, MIP-1 Beta, and RANTES in NT2 cells 
transfected with APP-GFP or GFP (control).  Samples were analyzed 24 hours post 
transfection.  Figure represents fold change in mRNA expression over control.  All 
experiments were done in triplicate.  Error bars represent standard deviation.  *Indicates 
statistical significance compared to control (IgG).  * Indicates statistical significance 
compared to control (*P<0.05). 
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Discussion 
 
Several studies have been done utilizing NT2 neuroprogenitor cells for 
transplantation.  The transplanted cells were shown to effectively migrate and 
incorporate with host tissue(Kleppner et al. 1995; Trojanowski et al. 1997; Ferrari et al. 
2000).  However, it is still unclear what factors are responsible for regulating NT2 cell 
migration and the intracellular signaling mechanism involved.  
This study provides the first evidence that MCP-1 is capable of inducing migration of 
NT2 neuroprogenitor cells.  Presently, the concentration of MCP-1 in the adult brain, 
particularly after injury, is not known.  It was reported that the concentration of MCP-1 in 
human brain tissue from control and alcoholic patients was 90 and 212 pg/mg, 
respectively(He and Crews 2008).  This demonstrates that altered conditions in the 
brain can have a dramatic effect on MCP-1 levels.  It is possible that the local 
concentration of MCP-1, especially after injury, may be even higher.  Previous in vitro 
studies examining MCP-1 induced migration used a concentration range of 0-200 ng/ml 
in human monocytes (Fine et al., 2001) and 0-250 ng/ml in hepatic stellate cells (Marra 
et al., 1999).  Thus, we adopted a similar MCP-1 concentration range (10-200 ng/ml) for 
this investigation.   Overall, these results suggest that MCP-1, which increases in 
response to brain injury and trauma, is likely a major factor causing neuroprogenitor 
cells to migrate to damaged regions of the brain(Glabinski et al. 1996) (Minami and 
Satoh 2003).  
Several studies have been done investigating the intracellular signaling pathways 
involved in chemokine induced migration(Nick et al. 1997; Yen et al. 1997; Ashida et al. 
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2001; Fine et al. 2001).  However, intracellular signaling in neuroprogenitor cells after 
exposure to MCP-1 or other chemotactic factors has never been examined.  Our results 
showed that ERK/MAPK inhibitor (PD098059) and p38 MAPK inhibitor (SB203580) 
have no effect on MCP-1 mediated chemotaxis.  These results are similar to previous 
studies where they demonstrate a minimal role for these kinases in leukocyte 
migration(Knall et al. 1997; Nick et al. 1997; Zu et al. 1998; Fine et al. 2001).  
Conversely, activation of either intracellular cAMP or protein kinase C (PKC) with 
forskolin and PMA, respectively, completely abolished MCP-1 induced migration.  
These results are in accord with an earlier study demonstrating activation of PKC and 
cAMP desensitize PMNs response to several chemokines(Fine et al. 2001).  It has also 
been reported that cAMP inhibits cell migration by preventing lamellipodia formation in 
mouse fibroblast cells(Chen et al. 2008).  Interestingly, another study showed that PKC 
is capable of phosphorylating specific adenylyl cyclase isoenzymes, resulting in 
increased levels of intracellular cAMP (Zimmermann and Taussig 1996; Marjamaki et al. 
1997).  Therefore, it is likely that treatment with PMA, not only activates PKC, but also 
elevates cAMP levels.  Further investigation is required to better understand the roles 
PKC and cAMP have in chemotactic inhibition of neuroprogenitor cells. 
Amyloid precursor protein (APP) is a ubiquitous glycoprotein receptor that is 
involved in pathogenesis of Alzheimer’s disease.  Previously, APP expression was 
shown to increase in response to cell death (Nishimura et al. 2003), where it is thought 
to serve a neuroprotective function (Lesort et al. 1997; Kinoshita et al. 2002).  Other 
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studies report that traumatic brain injury can induce expression of APP (Pierce et al. 
1996; Murakami et al. 1998; Ciallella et al. 2002).  
We demonstrate that NT2 cells transfected with APP act as a chemoattractant to 
other NT2 cells.  Since this effect was partially blocked by a MCP-1 neutralizing 
antibody, MCP-1 is involved in the mechanism of APP function, at least in part.  
However, use of MCP-1 neutralizing antibody could not completely abolish APP effect, 
indicating that this APP induced migration is not caused solely by increased MCP-1 
production.  
Although we found increased expression of RANTES and MIP-1 alpha, which are 
reported to be chemoattractants to monocytes (Fine et al. 2001), they may not affect 
NT2 cell migration.  Thus, further investigations are necessary to find additional factors, 
which are involved in the APP induced migration. 
 Taken together, these data demonstrate the novel role APP has in both 
chemokine production and cell migration.  It is possible that microenvironments in the 
CNS with increased levels of APP can have a significant effect on cell migration in that 
region.  This information is beneficial because it provides new insight into the factors 
that influence NT2 neuroprogenitor cell migration.  Further investigation of this 
mechanism would prove useful in future transplantation therapies by allowing better 
control of migrating cells and their incorporation into host tissues. 
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